ZA200006813B - Testosterone derivative. - Google Patents
Testosterone derivative. Download PDFInfo
- Publication number
- ZA200006813B ZA200006813B ZA200006813A ZA200006813A ZA200006813B ZA 200006813 B ZA200006813 B ZA 200006813B ZA 200006813 A ZA200006813 A ZA 200006813A ZA 200006813 A ZA200006813 A ZA 200006813A ZA 200006813 B ZA200006813 B ZA 200006813B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- ment
- ment undecanoate
- undecanoate
- androgen
- Prior art date
Links
- 150000003515 testosterones Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000003098 androgen Substances 0.000 claims description 27
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 claims description 25
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- -1 1-oxoundecyl Chemical group 0.000 claims description 4
- JFEPJTGMGDGPHJ-PNKHAZJDSA-N (8r,9s,10r,13s,14s)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 JFEPJTGMGDGPHJ-PNKHAZJDSA-N 0.000 claims description 3
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 11
- 229960003604 testosterone Drugs 0.000 description 11
- 230000001548 androgenic effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940030486 androgens Drugs 0.000 description 5
- 238000002657 hormone replacement therapy Methods 0.000 description 5
- 241000220438 Arachis Species 0.000 description 3
- 235000003911 Arachis Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 2
- 229960000746 testosterone undecanoate Drugs 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YSGQGNQWBLYHPE-UHFFFAOYSA-N 17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2(C)C(O)CCC2C2C(C)CC3=CC(=O)CCC3C21 YSGQGNQWBLYHPE-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JUKPJGZUFHCZQI-UHFFFAOYSA-N undecanoyl chloride Chemical compound CCCCCCCCCCC(Cl)=O JUKPJGZUFHCZQI-UHFFFAOYSA-N 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cultivation Receptacles Or Flower-Pots, Or Pots For Seedlings (AREA)
- Percussion Or Vibration Massage (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98202052 | 1998-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006813B true ZA200006813B (en) | 2002-02-21 |
Family
ID=8233831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006813A ZA200006813B (en) | 1998-06-19 | 2000-11-21 | Testosterone derivative. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US6437158B1 (he) |
| EP (1) | EP1087986B1 (he) |
| JP (1) | JP2002518514A (he) |
| KR (1) | KR100596649B1 (he) |
| CN (1) | CN1172949C (he) |
| AT (1) | ATE215961T1 (he) |
| AU (1) | AU756739B2 (he) |
| BR (1) | BR9911344A (he) |
| CA (1) | CA2333985C (he) |
| CZ (1) | CZ293319B6 (he) |
| DE (1) | DE69901250T2 (he) |
| DK (1) | DK1087986T3 (he) |
| ES (1) | ES2175989T3 (he) |
| HK (1) | HK1034263A1 (he) |
| HU (1) | HUP0102274A3 (he) |
| ID (1) | ID27260A (he) |
| IL (1) | IL139689A (he) |
| NO (1) | NO316518B1 (he) |
| NZ (1) | NZ508299A (he) |
| PL (1) | PL191285B1 (he) |
| PT (1) | PT1087986E (he) |
| RU (1) | RU2216546C2 (he) |
| SK (1) | SK282796B6 (he) |
| TR (1) | TR200003743T2 (he) |
| WO (1) | WO1999067271A1 (he) |
| ZA (1) | ZA200006813B (he) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE246703T1 (de) * | 1999-04-06 | 2003-08-15 | Akzo Nobel Nv | Oral wirksame 7-alpha-alkyl androgene |
| AU8201601A (en) * | 2000-07-28 | 2002-02-13 | Akzo Nobel Nv | 16alpha-methyl or ethyl substituted estrogens |
| JP3774888B2 (ja) * | 2001-11-28 | 2006-05-17 | 日本化薬株式会社 | ステロイド類化合物のｌｃ−ｍｓによる高感度検出法 |
| TW200400041A (en) * | 2002-05-30 | 2004-01-01 | Akzo Nobel Nv | Use of new etonogestrel esters |
| TW200403065A (en) | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| GB0304927D0 (en) | 2003-03-04 | 2003-04-09 | Resolution Chemicals Ltd | Process for the production of tibolone |
| JO2505B1 (en) | 2003-03-14 | 2009-10-05 | باير شيرنغ فارما اكتنجيسيلشافت | Pharmacy methods and formulations for obtaining acceptable serum testosterone levels |
| JO2492B1 (en) | 2003-04-28 | 2009-10-05 | شيرينج ايه جي | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients |
| PE20050677A1 (es) | 2003-12-22 | 2005-10-04 | Akzo Nobel Nv | Esteroides con perfil androgenico y progestagenico mixto |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| EP1879382B1 (en) | 2006-07-10 | 2017-09-06 | Samsung Electronics Co., Ltd. | Multi-screen display apparatus and method for digital broadcast receiver |
| WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
| US20090017107A1 (en) * | 2007-07-13 | 2009-01-15 | Oral Delivery Technology Ltd. | Novel composition to increase libido |
| US20090018107A1 (en) * | 2007-07-13 | 2009-01-15 | Oral Delivery Technology Ltd. | Novel composition to increase muscle strength |
| US20100303937A1 (en) * | 2009-06-01 | 2010-12-02 | Michael Farber | Novel composition to increase testosterone levels |
| CN102558267A (zh) * | 2012-01-13 | 2012-07-11 | 宜城市共同药业有限公司 | 庚酸睾酮的制备方法 |
| US9950125B2 (en) * | 2012-04-06 | 2018-04-24 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| PT2953667T (pt) | 2013-02-11 | 2020-01-28 | Antares Pharma Inc | Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342834A (en) | 1989-04-07 | 1994-08-30 | The Population Council, Inc. | Method for androgen supplementation |
-
1999
- 1999-06-14 CZ CZ20004779A patent/CZ293319B6/cs not_active IP Right Cessation
- 1999-06-14 DK DK99929208T patent/DK1087986T3/da active
- 1999-06-14 BR BR9911344-9A patent/BR9911344A/pt not_active Application Discontinuation
- 1999-06-14 CN CNB998075175A patent/CN1172949C/zh not_active Expired - Fee Related
- 1999-06-14 AU AU46101/99A patent/AU756739B2/en not_active Ceased
- 1999-06-14 SK SK1940-2000A patent/SK282796B6/sk not_active IP Right Cessation
- 1999-06-14 PL PL344987A patent/PL191285B1/pl not_active IP Right Cessation
- 1999-06-14 AT AT99929208T patent/ATE215961T1/de not_active IP Right Cessation
- 1999-06-14 ES ES99929208T patent/ES2175989T3/es not_active Expired - Lifetime
- 1999-06-14 DE DE69901250T patent/DE69901250T2/de not_active Expired - Fee Related
- 1999-06-14 US US09/719,927 patent/US6437158B1/en not_active Expired - Fee Related
- 1999-06-14 TR TR2000/03743T patent/TR200003743T2/xx unknown
- 1999-06-14 JP JP2000555922A patent/JP2002518514A/ja active Pending
- 1999-06-14 NZ NZ508299A patent/NZ508299A/xx unknown
- 1999-06-14 RU RU2001101892/04A patent/RU2216546C2/ru not_active IP Right Cessation
- 1999-06-14 KR KR1020007014182A patent/KR100596649B1/ko not_active IP Right Cessation
- 1999-06-14 WO PCT/EP1999/004102 patent/WO1999067271A1/en active IP Right Grant
- 1999-06-14 PT PT99929208T patent/PT1087986E/pt unknown
- 1999-06-14 EP EP99929208A patent/EP1087986B1/en not_active Expired - Lifetime
- 1999-06-14 IL IL13968999A patent/IL139689A/he not_active IP Right Cessation
- 1999-06-14 HU HU0102274A patent/HUP0102274A3/hu unknown
- 1999-06-14 CA CA002333985A patent/CA2333985C/en not_active Expired - Fee Related
- 1999-06-14 ID IDW20002632A patent/ID27260A/id unknown
-
2000
- 2000-11-21 ZA ZA200006813A patent/ZA200006813B/en unknown
- 2000-12-18 NO NO20006455A patent/NO316518B1/no unknown
-
2001
- 2001-07-10 HK HK01104759A patent/HK1034263A1/xx not_active IP Right Cessation
-
2002
- 2002-06-21 US US10/177,989 patent/US20040033999A1/en not_active Abandoned
-
2004
- 2004-10-13 US US10/964,076 patent/US6989378B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU756739B2 (en) | Testosterone derivative | |
| AU677181B2 (en) | Alkali metal 8,9-dehydroestrone sulfate esters | |
| Rapala et al. | The adamantyl group in medicinal agents. II. Anabolic steroid 17β-adamantoates | |
| EP1272196B1 (en) | Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha,11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use | |
| AU2001249661A1 (en) | Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use | |
| US20110195942A1 (en) | Method of making and using 7alpha, 11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate | |
| CA2171740C (en) | 0rally active derivatives of 1,3,5(10)-estratriene | |
| WO1999067270A1 (en) | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) | |
| NO168481B (no) | 14,17beta-ethano-14beta-oestratrienderivater, befruktningshindrende middel, og anvendelse derav for befruktningskontroll hos kvinner. | |
| MXPA00012805A (en) | Testosterone derivative | |
| EP1427748B1 (en) | 17alpha-hydroxy-14beta-steroids with hormonal effect | |
| EP1379253B1 (en) | Methods of making and pharmaceutical formulations comprising 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof | |
| AU2002258664A1 (en) | Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17-esters thereof |